Episurf Medical announced that the company's first commercial case in the US has been scheduled for surgery. This is also the first case ever with the newly introduced product Episealer® Patellofemoral System. The product is a fully individualized implant system for patients with isolated osteoarthritis of the patellofemoral joint in the knee.

Personalized implants for both sides of the joint, femur and patella, preserving as much bone and cartilage as possible by treating only the damaged areas of the joint, are designed uniquely for each individual patient. 510(k) clearance for the product for US market access was obtained late December 2022, and during 2023, Episurf Medical has prepared for the launch in the US market. Key activities have included the identification, contracting and training of distributors.

Currently, well over 20 distributors are signed across the US and several more are likely to be onboarded in the coming weeks and months.